With these new patents, Suven has a total of twenty granted patents from Europe and eight from Macau
The Dollar Business Bureau
The new patents are related to New Chemical Entities (NCEs) used in the treatment of disorders associated with neuro-degenerative diseases and are valid through 2030 and 2029.
Indian pharma major Suven Life Sciences on Tuesday announced that it has received patents for its two products from Europe and Macau regions.
The new patents are related to New Chemical Entities (NCEs) used in the treatment of disorders associated with neuro-degenerative diseases and are valid through 2030 and 2029.
With these new patents, Suven has a total of twenty granted patents from Europe and eight from Macau, the company said in a statement.
“We are very pleased by the grant of these patents to Suven for our pipeline of molecules in CNS arena that are being developed for Major Depressive Disorder (MDD) with high unmet medical need with huge market potential globally,” Suven CEO Venkat Jasti said.
In September, Suven had secured five product patents in China, Israel, Mexico, Singapore and Sri Lanka.
Besides Europe and Macau (as of September), Suven has got 17 patents from China, 7 from Israel, 20 from Mexico, 21 from Singapore and 11 from Sri Lanka.
Analysts say that multi-national pharma companies operating from developing countries, especially from BRICS (Brazil, Russia, India, China and South Africa), are expected to be the key drivers of revenue growth for the industry.
According to the Frost & Sullivan (F&S), China tops the group in local and foreign patent filings. The F&S analysis also said that the rise of resident applications has contributed to the patenting growth in China over the last few years.
In terms of non-resident patent applications among BRICS members, Brazil tops the list followed by India, Russia and China.
December 29, 2015 | 04:45pm IST